1. Home
  2. CHT vs ONC Comparison

CHT vs ONC Comparison

Compare CHT & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chunghwa Telecom Co. Ltd.

CHT

Chunghwa Telecom Co. Ltd.

N/A

Current Price

$49.91

Market Cap

36.8B

ML Signal

N/A

Logo BeiGene Ltd. American Depositary Shares

ONC

BeiGene Ltd. American Depositary Shares

N/A

Current Price

$415.95

Market Cap

40.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CHT
ONC
Founded
1996
2010
Country
Taiwan
Switzerland
Employees
N/A
12000
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.8B
40.6B
IPO Year
2003
2015

Fundamental Metrics

Financial Performance
Metric
CHT
ONC
Price
$49.91
$415.95
Analyst Decision
Strong Buy
Analyst Count
0
27
Target Price
N/A
★ $465.00
AVG Volume (30 Days)
129.3K
★ 442.0K
Earning Date
11-04-2026
11-05-2026
Dividend Yield
★ 2.55%
N/A
EPS Growth
N/A
★ 140.43
EPS
N/A
★ 0.56
Revenue
N/A
★ $238,387,000.00
Revenue This Year
$6.52
$29.05
Revenue Next Year
$1.44
$15.06
P/E Ratio
★ $26.66
$743.85
Revenue Growth
N/A
★ 22179.16
52 Week Low
$39.28
$253.95
52 Week High
$50.15
$424.73

Technical Indicators

Market Signals
Indicator
CHT
ONC
Relative Strength Index (RSI) 67.98 67.27
Support Level $41.92 $341.67
Resistance Level N/A N/A
Average True Range (ATR) 0.52 10.70
MACD -0.02 4.37
Stochastic Oscillator 82.95 88.77

Price Performance

Historical Comparison
CHT
ONC

About CHT Chunghwa Telecom Co. Ltd.

Chunghwa Telecom Co Ltd is Taiwan's integrated telecom operator, providing fixed-line, wireless, and Internet and data services. The company's reportable segments are: Consumer Business, Enterprise Business, International Business, and Others. The majority of its revenue comes from the Consumer Business, which focuses on individual and home-centric businesses, such as mobile, fixed broadband, Wi-Fi, IPTV (MOD), and OTT services. The Enterprise business offers IDC, cloud, cybersecurity, 5G, AIoT, data, AI, enterprise digital transformation, and system integration services to businesses, and the International business segment represents services offered to international customers. Geographically, the company generates maximum revenue from its business in Taiwan.

About ONC BeiGene Ltd. American Depositary Shares

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.

Share on Social Networks: